ODTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Odyssey Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$18.10+0.93 (+5.42%)

Close on Oct 19, 2026

Market cap: $548.01M
P/E (TTM): –
Dividend yield: –

Odyssey Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31
Cash & Equivalents	82	36	42	163	55	62
Short-Term Investments	229	140	140	–	–	–
Cash & Short-Term Investments	311	176	181	163	55	62
Receivables	0	0	0	0	0	0.44
Prepaid Expenses & Other	11	9.35	9.30	–	–	–
Total Current Assets	321	185	191	–	–	–
Property, Plant & Equipment	4.88	6.56	7.21	–	–	–
Gross Property, Plant & Equipment	18	22	21	–	–	–
Accumulated Depreciation	-13	-15	-14	–	–	–
Long-Term Investments	122	0	35	–	–	–
Operating Lease Right-of-Use Assets	17	18	19	0.30	–	–
Goodwill	14	14	14	–	–	–
Intangible Assets	0.09	0.16	0.26	–	–	–
Other Long-Term Assets	3.79	5.26	3.33	–	–	–
Total Assets	484	229	270	–	–	–
Accounts Payable	7.67	8.22	7.87	–	–	–
Accrued Expenses	15	8.62	13	–	–	–
Current Portion of Leases	5.47	5.37	5.21	–	–	–
Total Current Liabilities	28	22	26	–	–	–
Long-Term Leases	19	21	22	–	–	–
Operating Lease Liabilities	25	26	27	0.30	–	–
Total Liabilities	63	49	55	–	–	–
Preferred Stock	0	–	0	–	–	–
Common Stock	0.01	0	0	–	–	–
Additional Paid-In Capital	1,081	83	80	–	–	–
Retained Earnings	-659	-606	-568	–	–	–
Comprehensive Income & Other	-0.51	-0.15	0.25	–	–	–
Shareholders' Equity	421	-524	-488	-436	-417	-383
Total Equity	421	-524	-488	-436	-417	-383
Total Liabilities & Equity	484	229	270	–	–	–
Shares Outstanding(shares)	48	2.48	2.31	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 11.36
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 289.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.30
Dividend yield: –